DK2139479T3 - 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression - Google Patents

4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression

Info

Publication number
DK2139479T3
DK2139479T3 DK08715618.8T DK08715618T DK2139479T3 DK 2139479 T3 DK2139479 T3 DK 2139479T3 DK 08715618 T DK08715618 T DK 08715618T DK 2139479 T3 DK2139479 T3 DK 2139479T3
Authority
DK
Denmark
Prior art keywords
treatment
norepineprhin
methylphenylsulphanyl
melanic
adhd
Prior art date
Application number
DK08715618.8T
Other languages
English (en)
Inventor
Tine Bryan Stensboel
Silke Miller
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK2139479T3 publication Critical patent/DK2139479T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK08715618.8T 2007-03-20 2008-03-14 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression DK2139479T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PCT/DK2008/050064 WO2008113360A2 (en) 2007-03-20 2008-03-14 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression

Publications (1)

Publication Number Publication Date
DK2139479T3 true DK2139479T3 (da) 2013-02-11

Family

ID=39575680

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08715618.8T DK2139479T3 (da) 2007-03-20 2008-03-14 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression
DK08758225.0T DK2167085T3 (da) 2007-03-20 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl]piperidin til behandling af irritabel tarmsyndrom (ibs)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08758225.0T DK2167085T3 (da) 2007-03-20 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl]piperidin til behandling af irritabel tarmsyndrom (ibs)

Country Status (27)

Country Link
US (2) US20100144788A1 (da)
EP (2) EP2139479B1 (da)
JP (1) JP5388867B2 (da)
KR (1) KR20090125775A (da)
CN (2) CN101646438B (da)
AR (1) AR065798A1 (da)
AU (1) AU2008228639B2 (da)
BR (1) BRPI0808831A2 (da)
CA (1) CA2684556C (da)
CL (1) CL2008000796A1 (da)
CO (1) CO6220957A2 (da)
CY (2) CY1113965T1 (da)
DK (2) DK2139479T3 (da)
EA (1) EA017407B1 (da)
ES (2) ES2399305T3 (da)
HR (1) HRP20130049T1 (da)
IL (1) IL200954A (da)
MX (1) MX2009009934A (da)
MY (1) MY163537A (da)
NZ (1) NZ579723A (da)
PL (2) PL2139479T3 (da)
PT (2) PT2139479E (da)
RS (2) RS52676B (da)
SI (1) SI2139479T1 (da)
TW (1) TWI432194B (da)
UA (2) UA97660C2 (da)
WO (1) WO2008113360A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
SI2167085T1 (sl) * 2007-06-15 2014-05-30 H. Lundbeck A/S 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
ES2723029T3 (es) * 2010-04-30 2019-08-21 Takeda Pharmaceuticals Co Tableta entérica
US9311462B1 (en) * 2011-03-04 2016-04-12 Zynga Inc. Cross platform social networking authentication system
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
EP3478289A1 (en) 2016-07-01 2019-05-08 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958824A3 (en) * 1998-05-22 1999-12-01 Eli Lilly And Company Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
PL1635828T3 (pl) * 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
HK1142007A1 (en) 2010-11-26
US20100137366A1 (en) 2010-06-03
EP2167085A1 (en) 2010-03-31
WO2008113360A2 (en) 2008-09-25
DK2167085T3 (da) 2014-02-03
AU2008228639A1 (en) 2008-09-25
US20100144788A1 (en) 2010-06-10
RS52676B (sr) 2013-06-28
JP5388867B2 (ja) 2014-01-15
EP2139479B1 (en) 2012-12-12
PL2167085T3 (pl) 2014-08-29
EA017407B1 (ru) 2012-12-28
TWI432194B (zh) 2014-04-01
AR065798A1 (es) 2009-07-01
KR20090125775A (ko) 2009-12-07
UA99611C2 (ru) 2012-09-10
NZ579723A (en) 2011-07-29
PL2139479T3 (pl) 2013-05-31
CA2684556C (en) 2013-01-08
HRP20130049T1 (hr) 2013-02-28
CY1113965T1 (el) 2016-07-27
CN101646438B (zh) 2012-04-11
TW200848032A (en) 2008-12-16
JP2010521502A (ja) 2010-06-24
CL2008000796A1 (es) 2008-09-26
US8507526B2 (en) 2013-08-13
EP2139479A2 (en) 2010-01-06
IL200954A (en) 2014-12-31
SI2139479T1 (sl) 2013-04-30
PT2167085E (pt) 2014-02-17
PT2139479E (pt) 2013-02-20
BRPI0808831A2 (pt) 2014-08-26
AU2008228639B2 (en) 2012-12-13
EP2167085B1 (en) 2013-12-25
RS53138B (sr) 2014-06-30
CN101646438A (zh) 2010-02-10
WO2008113360A3 (en) 2008-11-13
CN101674830B (zh) 2012-05-09
MX2009009934A (es) 2009-09-24
CO6220957A2 (es) 2010-11-19
CA2684556A1 (en) 2008-09-25
CY1114774T1 (el) 2016-12-14
MY163537A (en) 2017-09-15
UA97660C2 (ru) 2012-03-12
CN101674830A (zh) 2010-03-17
ES2399305T3 (es) 2013-03-27
IL200954A0 (en) 2010-05-17
EA200970871A1 (ru) 2010-04-30
ES2445400T3 (es) 2014-03-03

Similar Documents

Publication Publication Date Title
DK2139479T3 (da) 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin med kombineret serotonin og norepineprhin genoptagelsesinhibering til behandlingen af adhd, melankoli, behandling af resistent depression eller restsymptomer af depression
NL301090I1 (nl) Entrectinib, dan wel tautomeren, of farmaceutisch aanvaardbare zouten daarvan
DK2426106T3 (da) Piperidin- og piperazinderivat til behandling af tumorer
DK1999225T3 (da) Fremgangsmåder til behandling af borehuller med genanvendelige fluider
DK2076260T3 (da) N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2069374T4 (da) Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes
DK1812528T3 (da) Viskoelastiske tensidfluider med forbedret retablering af formforandring, forbedret reologi og stabilitet
DK2200985T3 (da) 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
DK2234985T3 (da) 4-(4-cyano-2-thioaryl)-dihydropyrimidinoner og deres anvendelse
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
NO345119B1 (no) Fremgangsmåte for å forhindre og/eller hemme dannelse av uorganiske fluoridavsetninger
DK2142193T3 (da) 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine som forbindelse med kombineret serotoninoptagelse, 5-HT3 og 5-HT1A aktivitet til behandling af smerte eller restsymptomer i depression i forbindelse med søvn og kognition
DK3231798T3 (da) Thiazol-E-mellemprodukter, der er nyttige ved fremstillingen af RAF-kinasehæmmer
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
NO20082223L (no) Fremgangsmåte for inhibering av FLT3-kinase
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK2046331T3 (da) Anvendelse af 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion til behandling af mantle cellelymfom
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
EP1771442A4 (en) INHIBITORS OF VIRAL POLYMERASE
DK2358691T3 (da) Fremgangsmåde til fremstilling af piperazinforbindelser og hydrochloridsalte deraf
IL261853A (en) 6-[(4-fluorophenyl)methyl]-4-(3-nitrophenyl)-1,3-benzothiazole-2-amine and its salts
DK2158199T3 (da) Piperidinforbindelser og anvendelser deraf
DK1844039T3 (da) 5-substituerede quinolin- og isoquinolin-derivater, fremgangsmåde til fremstilling af disse og deres anvendelse som betændelseshæmmende midler
DK2358675T3 (da) 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser